Algorithmic bias in clinical research often begins at the recruitment stage.
Artificial intelligence is increasingly used to identify eligible patients from hospital databases or clinical registries. These tools enable faster screening, improved targeting, and potentially reduced recruitment timelines.
However, machine learning models replicate the biases present in their training datasets. If certain populations — such as elderly individuals, ethnic minorities, or socioeconomically disadvantaged patients — are underrepresented in historical datasets, algorithmic bias in clinical research may implicitly exclude them.
Source:
https://pmc.ncbi.nlm.nih.gov/articles/PMC6347576/
This risk is particularly concerning because recruitment decisions directly shape the external validity of a clinical trial.
The European Clinical Trials Regulation (Regulation (EU) No 536/2014) clearly states that participant protection and the generation of reliable, robust data must prevail over operational considerations. The European Medicines Agency (EMA) also emphasises the importance of methodological quality and data representativeness in regulatory submissions.
EMA – Clinical Trials Regulation
When algorithmic systems are used in recruitment processes, sponsors must therefore ensure that inclusion criteria are not unintentionally narrowed through hidden statistical distortions.
Representativeness and algorithmic bias in clinical research: a scientific and ethical challenge
A clinical trial must allow extrapolation of results to the real-world target population. When algorithmic bias in clinical research occurs during pre-selection, external validity may be compromised.
Scientific distortion is only part of the issue. Ethical implications are equally significant.
Several international ethical frameworks stress that artificial intelligence in healthcare must comply with principles of justice and equity. The World Health Organization (WHO), in its report on AI governance in health, underlines the necessity of avoiding algorithmic discrimination that could exacerbate inequalities in access to care.
WHO – Ethics and governance of artificial intelligence for health:
https://www.who.int/publications/i/item/9789240029200
Within the European context, these concerns intersect with GDPR requirements and ethical review obligations applicable to clinical trials. Ethics committees and competent authorities are increasingly required to assess not only clinical protocols, but also the methodological integrity of embedded AI systems.
Algorithmic bias in clinical research therefore represents both a regulatory and a moral challenge.
Model validation: the new regulatory frontier
Algorithmic bias in clinical research does not affect recruitment alone. It may also influence:
- patient stratification;
- imaging analysis;
- prediction of therapeutic response;
- detection of safety signals.
A model performing well on internal datasets is not necessarily generalisable to broader populations.
The journal The Lancet Digital Health frequently highlights the risks of insufficient validation, lack of independent external validation, and overfitting. These methodological weaknesses can amplify algorithmic bias in clinical research and undermine reproducibility.
The Lancet Digital Health – AI bias and validation issues:
https://www.thelancet.com/journals/landig/home
Poor validation practices may lead to exaggerated performance claims, misleading subgroup identification, or inaccurate safety monitoring — all of which directly impact regulatory assessment.
The European Medicines Agency now encourages detailed documentation of algorithmic methods used in clinical trials, particularly when decision-support tools or digital biomarkers are integrated into development programs.
EMA – Reflection paper on use of artificial intelligence in medicinal products:
Regulatory scrutiny is therefore expanding to include algorithmic transparency, dataset description, and performance metrics across diverse populations.
Towards strengthened governance
Algorithmic bias in clinical research raises multidimensional concerns:
- Scientific: validity and reproducibility of results
- Regulatory: compliance with European standards
- Ethical: equity of access to trials
- Strategic: credibility of data submitted for marketing authorisation
As AI becomes embedded in clinical development, controlling algorithmic bias is becoming a prerequisite for scientific robustness.
Several governance mechanisms are now considered essential:
- auditing of training datasets;
- independent external validation;
- transparency of model architecture and decision pathways;
- human oversight and multidisciplinary supervision.
Without these safeguards, algorithmic bias in clinical research could undermine both innovation and public trust.
Importantly, regulatory authorities are not opposed to AI integration. Rather, they expect structured governance frameworks ensuring that technological innovation does not compromise participant protection or data integrity.
Innovation must not compromise scientific integrity
Artificial intelligence offers undeniable opportunities to accelerate clinical research and improve analytical capabilities. However, algorithmic systems are not neutral. They reflect the data on which they are trained and the assumptions embedded in their design.
If not properly governed, algorithmic bias in clinical research may reinforce structural inequalities, distort trial populations, and weaken the robustness of submitted evidence.
Ultimately, clinical research remains guided by a fundamental principle: generating solid, representative and ethically responsible data — for the benefit of all patients.
Technological innovation can support this mission, but only if algorithmic bias in clinical research is actively identified, measured and mitigated.
In the era of AI-driven development, methodological vigilance is no longer optional. It is a scientific and regulatory imperative.
